Journal of Enzyme Inhibition and Medicinal Chemistry (Jan 2020)

Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction

  • Marcela Q. Granato,
  • Ingrid S. Sousa,
  • Thabatta L. S. A. Rosa,
  • Diego S. Gonçalves,
  • Sergio H. Seabra,
  • Daniela S. Alviano,
  • Maria C. V. Pessolani,
  • André L. S. Santos,
  • Lucimar F. Kneipp

DOI
https://doi.org/10.1080/14756366.2020.1724994
Journal volume & issue
Vol. 35, no. 1
pp. 629 – 638

Abstract

Read online

Phialophora verrucosa causes several fungal human diseases, mainly chromoblastomycosis, which is extremely difficult to treat. Several studies have shown that human immunodeficiency virus peptidase inhibitors (HIV-PIs) are attractive candidates for antifungal therapies. This work focused on studying the action of HIV-PIs on peptidase activity secreted by P. verrucosa and their effects on fungal proliferation and macrophage interaction. We detected a peptidase activity from P. verrucosa able to cleave albumin, sensitive to pepstatin A and HIV-PIs, especially lopinavir, ritonavir and amprenavir, showing for the first time that this fungus secretes aspartic-type peptidase. Furthermore, lopinavir, ritonavir and nelfinavir reduced the fungal growth, causing remarkable ultrastructural alterations. Lopinavir and ritonavir also affected the conidia-macrophage adhesion and macrophage killing. Interestingly, P. verrucosa had its growth inhibited by ritonavir combined with either itraconazole or ketoconazole. Collectively, our results support the antifungal action of HIV-PIs and their relevance as a possible alternative therapy for fungal infections.

Keywords